Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren’s syndrome-associated interstitial lung disease: A case report
Wei-Hung Hsu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · 2026
Read Molecular hydrogen is associated with immunophenotypic modulation and changes in T-cell exhaustion markers in refractory primary Sjögren’s syndrome-associated interstitial lung disease: A case report by Wei-Hung Hsu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13241678.txt.
Description
Wei-Hung Hsu and co-authors report a 2026 case of hydrogen therapy in stubborn lung disease linked to Sjögren syndrome. A 72-year-old woman had worsening breathlessness and lung scarring despite steroids, standard immune drugs, and a biologic therapy. She began taking oral molecular hydrogen capsules as an add-on.
Follow-up testing showed better gas exchange and stable scans, with no further scarring advance. A key antibody level fell. Blood cell profiling showed immune patterns shifting toward those of healthy people, including changes in T cell exhaustion markers. No side effects appeared. The authors urge caution, since earlier treatments might explain part of the change. They call for formal trials of hydrogen as an add-on therapy.
Catalog record
| CREATOR | Wei-Hung Hsu, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |